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We describe the case of a 62-year-old man who presented with shortness of breath that had progressed
over several years. He had a history of a paralyzed right hemidiaphragm for at least the previous 10 years.
He also reported weakness in his proximal legs and daytime sleepiness. On examination, he was found to
have thoracoabdominal paradox when in supine position. Pulmonary function testing revealed severe
restriction; arterial blood gas showed chronic respiratory acidosis. Electromyography showed chronic
phrenic neuropathy bilaterally, with mild proximal myopathy. Serum aldolase level was mildly elevated,
but serologic tests for connective tissue disorders were within reference range. After extensive clinical
investigations, the patient was found to have severely reduced acid a-glucosidase. Genetic analysis
conﬁrmed the diagnosis of adult-onset Pompe disease. The patient started treatment with bilevel pos-
itive airway pressure titrated during polysomnography, and acid a-glucosidase enzyme replacement was
recommended.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pompe disease is a rare genetic, autosomal recessive glycogen
storage disorder caused by an absence or a deﬁciency of the lyso-
somal enzyme acid a-glucosidase (GAA). Adult-onset Pompe dis-
ease is a rare cause of dyspnea, and its exact incidence in the United
States is not known. Nevertheless, this condition is necessary for a
clinician to keep in mind when considering the differential diag-
nosis of the causes of respiratory muscle weakness. Early recogni-
tion of Pompe disease can lead to the timely replacement of the
deﬁcient enzyme, which can be beneﬁcial to some patients with
this disease.
We report the case of an older man with severe restrictive lung
disease, hypercapnic respiratory failure, chronic phrenic neuropa-
thy bilaterally, and proximal muscle weakness who was found to
have Pompe disease. Our case highlights the diagnostic challenges
that clinicians may face while providing a work-up of this un-
common disease.AA, acid a-glucosidase.
Critical Care Medicine, Mayo
States.
).
Ltd. This is an open access article u1.1. Patient information
A 62-year-old man with a long history of apparently idiopathic
right hemidiaphragm paralysis presented with progressive short-
ness of breath, especially on exertion. He noted his symptoms to be
more prominent over the past 6 months. He could walk only 1 city
block at a slow pace before stopping because of breathlessness.
Additional symptoms were hypersomnolence during the day and
proximal muscle weakness with no sensory loss. His past medical
history included chronic obstructive pulmonary disease, diabetes
mellitus type 2, hypertension, hypercholesterolemia, and coronary
artery disease.
About 12 years previously, the patient had elevated serum cre-
atine kinase levels, after which statin therapy was discontinued. A
rheumatologic consult was obtained at that time, and no evidence
of connective tissue disease was found. At the same time, he also
underwent muscle biopsy and electromyography, both of which
showed nonspeciﬁc myopathic features associated with mild
denervation. The patient was lost to follow-up after these in-
vestigations. He was an exsmoker with 40e80 pack-years of
smoking. Medications at presentation to our facility included
aspirin, clopidogrel, simvastatin, diltiazem, sitagliptin, metformin,
budesonide and formoterol inhaler, tiotropium bromide inhaler,
and albuterol inhaler.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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On presentation, the patient's vital signs were a temperature of
36.5 C (97.7 F); heart rate, 94 beats/minute; blood pressure, 104/
70 mm Hg; respiratory rate, 22 breaths/minute; oxygen saturation,
90% when receiving 2 L of supplemental oxygen per minute; and
body mass index, 29.9 kg/m2. A general examination showed a man
with greater-than-ideal body weight who appeared sleepy. Chest
examination showed decreased air entry bilaterally. The rest of the
systemic examination was normal except for paradoxical respira-
tions on supine position: Respiratory distress immediately devel-
oped when he was lying ﬂat.1.3. Diagnostic assessment
The patient's laboratory values were the following: hemoglobin,
120 g/L; platelets, 279  109/L; white blood cells, 7.7  109/L; so-
dium, 140 mmol/L; potassium, 5.1 mmol/L; bicarbonate, 40 mmol/
L; serum urea nitrogen, 3.6 mmol/L; creatinine, 70.7 mmol/L; and
calcium, 2.48 mmol/L Fig. 1 shows posteroanterior and lateral plain
radiographs. Compared with prior images, computed tomography
of the patient's chest showed a stable, mild elevation of the right
hemidiaphragm, with bibasilar compressive atelectasis. Cen-
trilobular emphysema with upper lung predominance and with
fatty atrophy of paraspinal muscles and rotator cuff musculature
was also found (Fig. 2). Tests for resting room-air arterial blood
gases showed a pH of 7.29; PCO2, 89.4 mm Hg; PO2, 67.6 mm Hg;
and serum bicarbonate, 43 mmol/L. Pulmonary function test results
are shown in the Table 1.
Fluoroscopy showed right diaphragm paralysis and weakness in
left hemidiaphragm. These ﬁndings prompted a consultation with
neurology services. Electromyography showed complete absence of
phrenic compound muscle action potentials bilaterally. No activa-
tion of motor unit potentials was seenwithin the diaphragm, either
with respiration or with volitional effort. Ultrasonography showed
that the left hemidiaphragm was hyperechoic, 0.14 cm thick at
functional residual capacity (FRC), with a thickening ratio of 1.1 (the
thickening ratio is thickness at total lung capacity/thickness at FRC).
The right hemidiaphragm was hyperechoic, 0.15 cm thick at FRC,
with thickening ratio of 0.9. (Normal thickness is >0.15 cm, normal
thickening ratio is >1.2.) The aldolase concentration was slightly
increased at 9 U/L (reference level, <7.7 U/L). The following tests
were within reference range: creatine kinase, thyroid function
tests, erythrocyte sedimentation rate, serum and protein electro-
phoresis, antinuclear antibody proﬁle, and anti-Jo antibodies. To
complete the evaluation for rarer causes of diaphragmatic
dysfunction, neurology services requested testing for inheritedFig. 1. Hemidiaphragm With Bibasilar Atelectasis. Posteroanterior and lateral cneuropathies. Three weeks later, the patient's serum GAA level was
1.0 nmol/mL/hour (reference level, >7.4 nmol/mL/hour). This test
was followed by genetic testing, and the patient was found to have
c.525delT and c.-32-13T > G alterations, consistent with a diagnosis
of Pompe disease.
Therapeutic intervention replacement treatment with recom-
binant acid a-glucosidase (GAA) was started. Consultation with
sleep medicine services, followed by polysomnography, was ob-
tained, and the patient received a prescription for bilevel positive
airway pressure in the spontaneous, timed mode for respiratory
failure from restrictive lung disease. Results of follow-up blood
gases testing were pH of 7.40; PCO2, 46 mm Hg; PO2, 64 mm Hg;
and bicarbonate, 29 mmol/L.2. Discussion
Pompe disease, also known as glycogen storage disease type II,
was ﬁrst discovered by the Dutch pathologist Johann C. Pompe in
1932 when he carried out a postmortem examination of a 9-
month-old girl who died of pneumonia [1]. In the autopsy,
Pompe described accumulation of glycogen in muscle tissue. This
rare genetic (autosomal recessive) lysosomal storage disorder is
caused by the absence or deﬁciency of the lysosomal enzyme GAA.
Glycogen degradation requires this enzyme; when a person has
GAA deﬁciency, glycogen accumulates in tissues, although it mainly
affects cardiac, skeletal, and smooth muscles. In the United States,
the disease incidence of Pompe disease is not known. Three com-
mon mutations in the Dutch population have carrier frequencies
that implicate an estimated frequency of late-onset Pompe disease
as 1 in 57,000 persons [2].
Pompe disease is mainly divided into 2 types: infantile and late-
onset (presenting after 1 year of age). The infantile type presents
with cardiomegaly, generalized muscle weakness, hypotension,
enlarged tongue, and hepatomegaly [3,4]. This form results in se-
vere Pompe disease and poor prognosis. In the late-onset or adult
form, the heart and the liver are not involved. The late-onset form
can present at any age, with the major characteristics of proximal
muscle weakness and diaphragmatic involvement that leads to
respiratory failure [5e7].
In contrast to the other myopathies, the respiratory neuro-
muscular unit is particularly susceptible to involvement by Pompe
disease [8,9]. Nighttime respiratory difﬁculty usually precedes its
daytime symptoms [10]. Impaired cough and retained respiratory
secretions lead to frequent pneumonia bouts and ﬁnally to acute
respiratory failure. Approximately 60% of patients with late-onset
Pompe disease have mild reductions in vital capacity and, accord-
ing to 1 study, their vital capacity shows a variable, but in mosthest radiographs show an elevated right hemidiaphragm and atelectasis.
Fig. 2. Fatty Atrophy of Chest Musculature. Left panel, Fatty atrophy of right rotator cuff musculature (arrow). Right panel, Fatty atrophy of paraspinal muscles (arrows).
Table 1
Pulmonary function tests.
Function tested Value
FVC, L sitting 1.78
% predicted 39
FVC, L lying supine 1.36
% predicted 28
FEV1, L 1.20
% predicted 34
FEV1/FVC 69.6
PI max, cm H2O 27
% predicted 24
PE max, cm H2O 39
% predicted 19
MVV, L 38
% predicted 28
Abbreviations: FEV1, forced expiratory volume; FVC,
forced vital capacity; max, maximum; MVV, maximum
voluntary ventilation; PE, expiratory pressure; PI,
inspiratory pressure.
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decline of 1.6% per year [11]. Severe respiratory failure can occur
independent of limb muscle weakness and is reported to be the
most common cause of death [12].
Our patient had substantial phrenic nerve neuropathy. Newer
studies support the ﬁnding that lysosomal dysfunction can lead to
neuronal cell death. DeRuisseau et al. [13] provided a histologic
description of phrenic motoneurons in the C4 spinal cord that
showed swollen cell bodies, and biochemical survey indicated
accumulation of glycogen. This phrenic motoneuron pathologic
change contributes substantially to diaphragm motor deﬁcits seen
in Pompe disease [14,15].
The diagnosis of late-onset Pompe disease is usually delayed
because of the heterogeneity of the disease. GAA activity ranges
from about 1% to 40% and hence presents with variable manifes-
tations and disease severity [16,17]. The symptoms canmimic other
neuromuscular disease, and the tests usually performed for these
patients, such as electromyography and muscle biopsy, may not
provide the answer. Creatine kinase levels are usually elevated but
can be at reference level, as in our patient [18]. Thus, the clinician
must maintain a high index of suspicion in order to reach the
diagnosis.
We did not perform muscle biopsy in our patient. However,
when muscle biopsy shows abnormal glycogen accumulation and a
vacuolar neuropathy, it is diagnostic for Pompe disease [19]. The
diagnostic challenge is that vacuoles may not always contain
glycogen, and electron microscopy may be needed for detection.The extent to which vacuolization occurs varies from patient to
patient; even within the same patient, differences in vacuolization
can occur among different muscles and ﬁber types [20].
The gold standard for diagnostic testing in Pompe disease is the
ﬁnding of reduced or absent GAA activity either in blood, a cultured
ﬁbroblast, or muscle. Since the testing level of this enzyme can be
falsely low, the diagnosis is usually made by either combining the
enzyme activity test with DNA mutation analysis for GAA gene
sequencing or with repeating the measurement of GAA level in a
second sample [21].
In 2006, enzyme replacement therapy with alglucosidase-a for
Pompe diseasewas approved in the United States and the European
Union. In a randomized, double-blind placebo-controlled study of
90 patients with late-onset Pompe disease, van der Ploeg et al. [22]
found a signiﬁcant improvement in the 6-min walk test, as well as
forced vital capacity [FVC], at 78 weeks of enzyme replacement
therapy. This effect was observed in all the study's participants but
was more pronounced in patients with better clinical status at the
baseline. These ﬁndings reinforce that early diagnosis and the
institution of treatment are essential to prevent progressive loss in
function.
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